Insights

Insights From Our Experts

Articles

Navigating the Evolving Landscape of Internet Healthcare in China: Development Status, Challenges, and Future Prospects

Authors: Robin Arnold, Executive Vice President; Renyang Liu, Engagement Manager; Erica Wang, Associate Consultant  Background Internet healthcare means using the internet to provide health and medical services. China has implemented “Internet Plus Healthcare” as a national…

Unveiling the Future: AI Opportunities in FDA Compliance, Insights from the OPQ Symposium

In the dynamic realm of pharmaceuticals, staying ahead of the curve is not just an advantage; it’s a necessity. Recently, our team had the privilege of attending the CDER’s Office of Pharmaceutical Quality (OPQ) symposium, where…

Driving Patient-First Affordability in Seconds – Not Days: Accelerating Time to Therapy

Fewer than 60% of Pharmacy Benefit Manager (PBM) electronic benefit verifications (eBVs) accurately assess patients’ financial responsibilities, largely due to the industry’s reliance on AI algorithms for estimations. This leads to financial barriers for patients, hesitancy…

Adapting to Change: Examining the Implications of New EU Regulations on Commercialisation from the Perspectives of Patients, Providers, and Pharma Companies

In April, the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) 2022 Patient W.A.I.T Indicator found that the average rate of availability for pharmaceuticals in Europe is 45%, down 2% on the previous year. Additionally, the…

Utilization of Indirect Treatment Comparison (ITC), External Control Arms (ECA) and Patient-Reported Outcome Measures (PROMs)

Health Technology Assessment (HTA) is crucial to assessing the effectiveness, safety and cost-effectiveness of healthcare interventions. Indirect Treatment Comparison (ITC) is one trend that has gained traction in the HTA space as a way to evaluate…

APACMed Digital Health Reimbursement Policy Forum

Introduction The APACMed Policy Forum on Digital Health Reimbursement was held on 23 May 2023, with participants from Australia, Japan, Singapore, South Korea, Germany, France, and the UK. Several digital health policymakers, academicians, and experts from…

Considerations for Globalization of Medical Information Services: A Service Partner Perspective

This poster details the considerations for globalizing medical information (MI) services. Traditionally, pharmaceutical companies began in one geographical region before expanding, but evolving regulations and research priorities for rare diseases, oncology/hematology, immunology, and cell and gene…

New Models of Benefits Verification Solve for Complexity, Accelerate Speed to Therapy and Deliver Price Transparency

Navigating health care insurance coverage can be a supremely convoluted process for anyone, especially patients or caregivers recently faced with coping with a life-threatening disease. While the advancement of many new treatments and scientific innovations in…

Balancing the Portfolio: How Extending Mature Brands’ Success Can Replenish Costs Invested In Launching New Products

The traditional mindset toward established brands in the pharmaceutical industry has largely been to let focus fade from them and shift entirely to developing and launching new products. With emphasis placed almost exclusively on new product…

Asset Optimization: Breathe New Life Into Mature Brands with EVERSANA REIGNITE™

Maximizing revenue potential throughout products’ entire lifecycles before they reach loss of exclusivity (LOE) is the most impactful return on investment manufacturers can make for their established brands. While many companies figuratively put their mature brands…